Call for Schools proposals from EASL Members
In early 2016, the EASL Governing Board initiated a new format for its Schools of Hepatology. In September of the same year, the first pilot of this new format was executed successfully and received overwhelmingly positive feedback from participants. The EASL Schools of Hepatology have…
Announcing our Annual Report 2020: hot off the press
An Annual Report with a difference, for a year like none other
Journal of Hepatology ranking soars, remaining the leader among specialist hepatology journals
ClarivateTM Analytics released the 2021 update of its Journal Citation Reports©, including the much anticipated 2020 impact factor. EASL’s flagship monthly journal, the Journal of Hepatology, achieved unprecedented results with a 2020…
Discover the making-of the International Liver Congress 2021
We would like to thank every single participant who took part in this year's ILC, held 23–26 June 2021. The event brought together almost 6,500 delegates from over 100 countries, who took…
Treatment advances for Non-Alcoholic Fatty Liver Disease (NAFLD) announced at ILC 2021
For Immediate Release Media Release Treatment advances for Non-Alcoholic Fatty Liver Disease (NAFLD) announced at ILC 2021 New data released on trials involving RNAi therapeutics, antivirals and structurally engineered fatty acids to…
A highlight of ILC 2021: a triumvirate of Nobel Laureates
In EASL Studio, we were honoured to keep company with the three 2020 Nobel Laureates, awarded the 2020 Nobel Prize for Physiology and Medicine for their discovery of the hepatitis C virus.…
Advances in new drugs to for curing Hepatitis B and Hepatitis D announced at ILC 2021
For Immediate Release Media Release Advances in new drugs to for curing Hepatitis B and Hepatitis D announced at ILC 2021 Thursday 24 June 2021 (Geneva, Switzerland)-- Leading hepatology researchers announced important…
